On March 22, 2023 XNK Therapeutics AB reported its extensive participation at the 8th Annual Innate Killer Summit in La Jolla, San Diego, CA, March 28-30 (Press release, XNK Therapeutics, MAR 22, 2023, View Source [SID1234629189]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Annual Innate Killer Summit is the largest and leading technical, industry-focused, end-to-end innate immune cell therapy meeting to explore frontiers in immunobiology, genetic modification, clinical translation, scalable manufacturing, cryopreservation, and CMC. Over 200 experts from both pharmaceutical industry and academia participate to advance the clinical and phase development of NK, macrophage, γδT and NKT cell therapies for liquid and solid tumors.

On March 29, XNK’s CMO Peter Hovstadius, M.D., Ph.D. will discuss the potential risks and benefits of repeat dosing in NK cell therapy.

On March 29, XNK’s Head of Manufacturing and Engineering Paul Do, will discuss how a tailor-made in-house GMP facility can provide a fast track to ensure efficient process development and robust manufacturing capability.

On March 30, there is a panel discussion with the title ‘What does the future of innate therapies look like? Is it out-patient care?’. Johan Liwing, CEO of XNK, will discuss this important topic with Daniel Teper CEO at Cytovia Therapeutics and Peter Flynn, COO at Artiva Bio.

"We are very excited to have been invited to participate at this prestigious conference. Discussing key topics like clinical development aspects, manufacturing processes as well as the future landscape of NK-cell therapies shows that XNK is at the forefront of NK cell therapy today," said Johan Liwing, CEO.